Home World News Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological... World News Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 515 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer December 1, 2023 Foodie Friday: What to do with all these zucchini? July 9, 2021 News digest – Genetic links to male breast cancer, bowel cancer... August 15, 2020 Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated... September 10, 2026 Load more HOT NEWS One Year in Cancer Research and Much to Celebrate Selumetinib Approved by FDA to Treat Children with NF1 Kid Friendly Meals Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans
